Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Systemic lupus /certified fixed orthodontic courses by Indian dental academy

655 views

Published on


The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.

Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
0091-9248678078

  • Be the first to comment

Systemic lupus /certified fixed orthodontic courses by Indian dental academy

  1. 1. Systemic Lupus Erythematosus (SLE) INDIAN DENTAL ACADEMY Leader in continuing dental education www.indiandentalacademy.com www.indiandentalacademy.com
  2. 2. Autoimmune Diseases Autoimmune Disease Systemic Autoimmune Disease Responses seen in SLE Autoantibodies found in SLE www.indiandentalacademy.com
  3. 3. Systemic Lupus Erythematosus Course of Disease & Causes of Death Clinical Symptoms What causes these symptoms? www.indiandentalacademy.com
  4. 4. What Causes SLE Cause is unknown Possible factors  Genetic  Environmental www.indiandentalacademy.com
  5. 5. What Happens? Loss of self-non-self recognition Diversification of antigen-driven responses Hyperactivity of T & B Cells Formation of immune complexes Type III hypersensitivity reaction www.indiandentalacademy.com
  6. 6. Loss of T-cell Tolerance  T-Cells found in healthy & diseased patients  Loss of self-non-self recognition allows T-Cells to react with self antigen www.indiandentalacademy.com
  7. 7. Pathogenesis once T-cell tolerance is lost www.indiandentalacademy.com
  8. 8. Type III Hypersensitivity Reaction (Immune Complex-Mediated) Hyperactivity of T and B-cells Formation of immune complexes Clearance via the complement system Type III Hypersensitivity Reaction Tissue damage www.indiandentalacademy.com
  9. 9. Therapies for SLE 1st Therapies Cytotoxic drugs Current Therapies Immunosuppressions Cyclophosphamide Mycophenolate Mofetil Future Therapies Hormonal modulation Cytokine inhibition www.indiandentalacademy.com
  10. 10. Key Concepts * Self-non-self * Specificity Memory www.indiandentalacademy.com
  11. 11. References  Baechler E, Gregersen P, Behrens T. 2004. The emerging role of interferon in human systemic lupus erythematosus. Current Opinion in Immunology 16: 801-807.  Blatt N, Glick G. 1999. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacology and Therapeutics 83: 125-139.  Brogan P, Dillon M. 2005. Autoimmune diseases in children. Current Paediatrics 15: 23-31.  Franchin G, Peeva E, Diamond B. 2004. Pathogenesis of SLE: implications for rational therapy. Drug Discovery Today: Disease Mechanisms 1: 303-308.  Hoffman R. 2004. T cells in the pathogenesis of systemic lupus erythematosus. Clinical Immunology 113: 4-13.  Kaplan M. 2004. Apoptosis in systemic lupus erythematosus. Clinical Immunology 112: 210-218.  Renaudineau Y, Pers J, Bendaoud B, Jamin C, Youinou P. 2004. Dysfunctional B cells in systemic lupus erythematosus. Autoimmunity Reviews 3: 516-523.  Sidiropoulos P, Bertsias G, Kritikos H, Boumpas D. 2004. Therapeutic strategies for refractory systemic lupus erythematosus. Drug Discovery Today: Therapeutic Strategies 3: 375-382.  Singh R. 2004. Prevention and control of reciprocal T-B cell diversification: implications for lupuslike autoimmunity. Molecular Immunology 40: 1137-1145.  Tsukamoto H, Horiuchi T, Kokuba H, Nagae S, Nishizaka H, Sawabe T, Harashima S, Himeji D, Koyama T, Otsuka J, and others. 2005. Molecular analysis of a novel hereditary C3 deficiency with systemic lupus erythematosus. Biochemical and Biophysical Research Communications 330: 298-304. www.indiandentalacademy.com
  12. 12. Thank you For more details please visit www.indiandentalacademy.com www.indiandentalacademy.com

×